Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DARE
Bullish
medium confidence
Mentioned
$DARE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DAREBullishMed
01

Why it matters

The update emphasizes operational milestones for its commercial products (sildenafil cream dispensing via 503B, Flora Sync LF5 early orders and reorder signals) and continued pipeline advancement supported by non-dilutive grant funding.

02

Market read

Traders can reassess near-term commercialization execution risk and the probability of a 2026-to-2027 revenue ramp as dispensing begins and early repeat-demand signals emerge.

03

What to watch

The filing emphasizes operational progress but does not provide quantified revenue, margin, or guidance figures in the excerpt, leaving investors to underwrite execution risk into 2027 launches.

Relevance 7/10Novelty 6/10Timing: today’s 4:30 p.m. ET conference call, plus dispensing expected later this month

Background

Daré Bioscience filed an 8-K with Q3 2026 results and a corporate update focused on commercial execution and pipeline progress.

Company-level read

Ticker impact

$DAREBullishMedium confidence
Context

Daré Bioscience reports Q3 2026 results and says DARE to PLAY sildenafil cream dispensing is expected this month after first shipment to Medvantx.

Expected impact

Likely positive bias as investors price in earlier-than-expected commercialization execution and broader state coverage.

Evidence & confidence

The filing provides specific commercialization milestones (shipment on route, dispensing expected this month, prescriptions across 48 states) rather than only high-level strategy, which can move biotech sentiment and forward revenue expectations.

Market effects

Highlights the importance of 503B compounding execution and provider-office engagement for women’s health commercialization.

No clear regional market transmission beyond US biotech sentiment.

Limited, as the update is US-focused (48 states, Medvantx, Amazon launch timing).

Counterpoint

Early orders and provider prescriptions may not translate into sustained repeat purchases, and dispensing timelines can slip with compounding and state licensing.

Key entities

  • Daré Bioscience, Inc.

    NASDAQ-listed women’s health biotech reporting Q3 2026 results and commercialization progress.

  • DARE to PLAY Sildenafil Cream

    Topical sildenafil cream preparing for prescription dispensing via the Section 503B compounding pathway.

  • Flora Sync LF5

    Launched in June 2026, with early orders from 27 states and provider office reorder.

  • DARE-IDDS platform

    Programmable drug delivery technology underlying DARE-LARC1, explored for applications including obesity, diabetes, hormone therapies, and neurologic disease.

Related articles

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

$DAREMed

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to